welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today the recipients of its Route 79, The Duchenne Scholarship Program. Launched in March 2018, the Scholarship Program was created to recognize exceptional individuals dedicated to pursuing their post-secondary education. Ten recipients were chosen by an independent selection committee comprised of Duchenne community members based on each applicant’s community involvement and a personal essay. Each of the 10 students will receive scholarships of up to $10,000.

Sarepta Therapeutics Announces Recipients Of Route 79, The Duchenne Scholarship Program